The American Society of Hematology, has entered into an agreement with Doctor Evidence to host ASH annual meeting abstracts in DRE’s innovative DOC Search platform.
| WASHINGTON, Oct. 26, 2018 /PRNewswire/ -- The American Society of Hematology (ASH), has entered into an agreement with Doctor Evidence (DRE) to host ASH annual meeting abstracts in DRE’s innovative DOC Search artificial intelligence technology platform. ASH is the world’s largest professional society serving both clinicians and scientists around the world who are working to conquer blood diseases. This subscription offering includes all abstract content back to 2016 along with the current year’s annual meeting abstracts as they are released from embargo, thus enabling researchers to longitudinally probe and track data, methods, results, and changing research foci in the fields of hematology and oncology. Subscribers of the new offering will be required to have an active subscription to Blood. The DOC Search platform, powered by artificial intelligence, deep machine learning, and a robust ontology system, enables cutting edge research capabilities. Meeting abstracts are linked to clinicaltrials.gov registrations and other publications addressing the same clinical trial populations, so researchers can follow cohorts over time and avoid double counting patients. Most influential authors can be identified along with their coauthor networks, affiliations, and other publications. Saved signals can be set to monitor for future content matching specific search terms. Descriptive statistics, distributions, and frequent co-occurring concepts (characteristics, interventions, and outcomes) are instantly displayed for the set of abstracts matching each search query. “ASH is the preeminent research organization in hematology and hematologic diseases. We are pleased to provide our artificial intelligence technological solutions to promote and advance the important research presented at their annual meetings,” said Robert Battista, CEO of Doctor Evidence. “DRE’s capabilities for structuring and synthesizing complex data maximizes the agility of insights for the hematology research community.” “The ability to more thoroughly and longitudinally probe the research output of hematology investigators should benefit ASH members and our field immensely,” said Chair of the ASH Publications Committee David Scadden, MD, of Massachusetts General Hospital and the Harvard Stem Cell Institute. “It is a strong start to using machine learning to advance our understanding of blood diseases, which will lead to improvements in patient care.” About Doctor Evidence: About American Society of Hematology:
SOURCE Doctor Evidence |
View original content:
